Skip to main content

Coronavirus Infections

Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.

Parker EPK. eBioMedicine 2026;:https://doi.org/10.1016/j.ebiom.2026.106327.

Published on 13/7/2026
Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19.

Agyeman AA. British Journal of Clinical Pharmacology 2026;92(7):2390-2402.

Published on 21/7/2026
An online singing-based breathing and wellbeing programme (ENO Breathe) in people with long COVID breathlessness in the UK: a cohort study.

The Lancet Digital Health; 2026.

Published on 19/6/2026
Community-delivered hyperbaric oxygen therapy for people affected by long COVID: a pilot study.

Gale N. British Journal of Nursing 2026;35(12):626-632.

Published on 2/8/2026
Lessons from the COVID-19 pandemic for future primary care: a qualitative interview study with GPs and medical practice assistants in Germany.

Toutaoui K. BJGP Open 2026;:BJGPO.2025.0075.

Published on 17/6/2026
Effects of antibiotic treatment on clinical outcomes in patients with COVID-19: a systematic review and meta-analysis.

Dona D. The Lancet Microbe 2026;:https://doi.org/10.1016/j.lanmic.2026.101358.

Published on 16/6/2026
Epidemiology and severity of pediatric influenza hospitalizations before and during the COVID-19 pandemic: a surveillance study of the Canadian immunization monitoring program (IMPACT), 2012–2023.

Di Chiara C. The Lancet Regional Health – Americas 2026;:https://doi.org/10.1016/j.lana.2026.101525.

Published on 16/6/2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.

Morgan E. The Lancet Oncology 2026;:https://doi.org/10.1016/S1470-2045(26)00089-6.

Published on 16/6/2026
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.

Hayden FG. New England Journal of Medicine 2026;394(19):1905-1915.

Published on 15/6/2026
Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

Engel JJ. British Journal of Clinical Pharmacology 2026;92(6):1685-1695.

Published on 7/6/2026

1
2
3
4
5
...